ES2558434T3 - Tratamiento de leucemia linfoblástica aguda - Google Patents
Tratamiento de leucemia linfoblástica aguda Download PDFInfo
- Publication number
- ES2558434T3 ES2558434T3 ES09760483.9T ES09760483T ES2558434T3 ES 2558434 T3 ES2558434 T3 ES 2558434T3 ES 09760483 T ES09760483 T ES 09760483T ES 2558434 T3 ES2558434 T3 ES 2558434T3
- Authority
- ES
- Spain
- Prior art keywords
- bispecific single
- patient
- single stranded
- cd19xcd3
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 title claims abstract description 163
- 238000011282 treatment Methods 0.000 title claims abstract description 99
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 title claims description 115
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 title claims description 113
- 238000000034 method Methods 0.000 claims abstract description 73
- 230000006872 improvement Effects 0.000 claims abstract description 19
- 230000008030 elimination Effects 0.000 claims abstract description 15
- 238000003379 elimination reaction Methods 0.000 claims abstract description 15
- 208000007660 Residual Neoplasm Diseases 0.000 claims description 82
- 108091008874 T cell receptors Proteins 0.000 claims description 39
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 38
- 238000002512 chemotherapy Methods 0.000 claims description 36
- 230000008521 reorganization Effects 0.000 claims description 36
- 230000000735 allogeneic effect Effects 0.000 claims description 34
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 230000005945 translocation Effects 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 238000001802 infusion Methods 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 21
- 230000004927 fusion Effects 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
- 230000002489 hematologic effect Effects 0.000 claims description 14
- 238000010276 construction Methods 0.000 claims description 12
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 12
- 239000002243 precursor Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000007596 consolidation process Methods 0.000 claims description 9
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 claims description 5
- 238000010222 PCR analysis Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 41
- 238000002560 therapeutic procedure Methods 0.000 description 32
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 25
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 description 21
- 108060003951 Immunoglobulin Proteins 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 102000018358 immunoglobulin Human genes 0.000 description 20
- 208000032839 leukemia Diseases 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 18
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 18
- 230000004044 response Effects 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000002054 transplantation Methods 0.000 description 12
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 12
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000002559 cytogenic effect Effects 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 229960003008 blinatumomab Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229960002411 imatinib Drugs 0.000 description 4
- 210000004214 philadelphia chromosome Anatomy 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000011476 stem cell transplantation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000009115 maintenance therapy Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 231100000755 favorable toxicity profile Toxicity 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- -1 imatinib tyrosine kinase inhibitor Chemical class 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000011255 standard chemotherapy Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108020005098 Anticodon Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000032953 Device battery issue Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 206010024325 Leukaemic lymphoma Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011419 induction treatment Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000002914 neoplasic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11232308P | 2008-11-07 | 2008-11-07 | |
| US112323P | 2008-11-07 | ||
| US18329109P | 2009-06-02 | 2009-06-02 | |
| US183291P | 2009-06-02 | ||
| PCT/EP2009/007970 WO2010052014A1 (en) | 2008-11-07 | 2009-11-06 | Treatment of acute lymphoblastic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2558434T3 true ES2558434T3 (es) | 2016-02-04 |
Family
ID=41692882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15185767T Active ES2727585T3 (es) | 2008-11-07 | 2009-11-06 | Tratamiento de leucemia linfoblástica aguda |
| ES09760483.9T Active ES2558434T3 (es) | 2008-11-07 | 2009-11-06 | Tratamiento de leucemia linfoblástica aguda |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15185767T Active ES2727585T3 (es) | 2008-11-07 | 2009-11-06 | Tratamiento de leucemia linfoblástica aguda |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20130323247A1 (ru) |
| EP (2) | EP2982696B1 (ru) |
| JP (2) | JP5647132B2 (ru) |
| KR (1) | KR101695327B1 (ru) |
| CN (2) | CN107184977A (ru) |
| AU (4) | AU2009313040B2 (ru) |
| BR (1) | BRPI0921482B1 (ru) |
| CA (1) | CA2742249C (ru) |
| CY (2) | CY1117033T1 (ru) |
| DK (2) | DK2342227T3 (ru) |
| ES (2) | ES2727585T3 (ru) |
| HK (2) | HK1158668A1 (ru) |
| HR (2) | HRP20151168T1 (ru) |
| HU (2) | HUE028175T2 (ru) |
| IL (1) | IL212652A (ru) |
| LT (1) | LT2982696T (ru) |
| ME (2) | ME03480B (ru) |
| MX (1) | MX2011002927A (ru) |
| NZ (1) | NZ591311A (ru) |
| PL (2) | PL2342227T3 (ru) |
| PT (2) | PT2342227E (ru) |
| RS (2) | RS58827B1 (ru) |
| RU (1) | RU2536940C2 (ru) |
| SI (2) | SI2342227T1 (ru) |
| SM (1) | SMT201500328B (ru) |
| WO (1) | WO2010052014A1 (ru) |
| ZA (1) | ZA201103255B (ru) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1976886T3 (pl) * | 2005-12-16 | 2015-06-30 | Amgen Res Munich Gmbh | Środki i metody do leczenia chorób nowotworowych |
| BRPI0921482B1 (pt) * | 2008-11-07 | 2022-09-20 | Amgen Research (Munich) Gmbh | Uso de uma construção de anticorpo de cadeia simples biespecífica cd19xcd3 no tratamento de leucemia linfoblástica aguda |
| ES2552655T5 (es) | 2009-10-27 | 2021-10-27 | Amgen Res Munich Gmbh | Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 |
| PL3412687T3 (pl) * | 2010-10-27 | 2020-07-27 | Amgen Research (Munich) Gmbh | Sposoby leczenia dlbcl |
| FI2637670T4 (fi) * | 2010-11-10 | 2024-03-19 | Amgen Research Munich Gmbh | Cd3-spesifisten sitoutumisdomeenien aiheuttamien haittavaikutusten estäminen |
| EP2701741B1 (en) * | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US10106623B2 (en) * | 2014-02-12 | 2018-10-23 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| HRP20231361T1 (hr) | 2014-05-30 | 2024-02-16 | Amgen Research (Munich) Gmbh | Stratifikacija rizika bolesnika s b-prekursorskom akutnom limfoblastičnom leukemijom |
| ES2890669T3 (es) | 2014-09-09 | 2022-01-21 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-CD38 |
| EA037084B9 (ru) | 2014-12-04 | 2021-08-05 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| US20180021331A1 (en) * | 2014-12-30 | 2018-01-25 | University Of Utah Research Foundation | Hdac1,2 inhibitors and methods of using the same |
| US10563194B2 (en) | 2015-02-24 | 2020-02-18 | BioAlta, LLC | Conditionally active biological proteins |
| SG10201914069SA (en) * | 2015-05-18 | 2020-03-30 | Tcr2 Therapeutics Inc | Compositions and methods for tcr reprogramming using fusion proteins |
| KR102602754B1 (ko) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
| AU2016263464B2 (en) * | 2015-05-20 | 2021-12-23 | Amgen Research (Munich) Gmbh | B-cell depletion as a diagnostic marker |
| AU2016282674B2 (en) | 2015-06-22 | 2022-01-13 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| CN105154440B (zh) * | 2015-08-14 | 2016-11-30 | 深圳市瀚海基因生物科技有限公司 | 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法 |
| US10385135B2 (en) | 2015-11-03 | 2019-08-20 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| RU2651776C2 (ru) * | 2015-12-01 | 2018-04-23 | Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") | Биспецифические антитела против cd3*cd19 |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| US11242376B2 (en) | 2016-08-02 | 2022-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| IL302917A (en) | 2016-10-07 | 2023-07-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
| US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| KR20200096814A (ko) * | 2017-12-11 | 2020-08-13 | 암젠 인크 | 이중특이적 항체 생성물의 연속 제조 공정 |
| KR102083481B1 (ko) | 2018-03-22 | 2020-03-02 | 강원대학교산학협력단 | 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물 |
| WO2020132810A1 (en) * | 2018-12-24 | 2020-07-02 | Generon (Shanghai) Corporation Ltd. | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| JOP20210298A1 (ar) | 2019-05-14 | 2023-01-30 | Provention Bio Inc | طرق وتركيبات للوقاية من مرض السكري من النوع الأول |
| WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CA3194771A1 (en) | 2020-09-16 | 2022-03-24 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| AU2022364154A1 (en) | 2021-10-15 | 2024-04-04 | Amgen Research (Munich) Gmbh | Subcutaneous administration of cd19-binding t cell engaging antibodies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008875A1 (de) * | 1996-08-28 | 1998-03-05 | Viva Diagnostika Diagnostische Produkte Gmbh | Kombinationspräparationen und ihre verwendung in der immundiagnostik und immuntherapie |
| BG65066B1 (bg) * | 1998-04-21 | 2007-01-31 | Micromet Gessellschaft Fur Biomedicinische Forschung Mbh | CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ |
| DK1071752T3 (da) * | 1998-04-21 | 2003-10-20 | Micromet Ag | CD19xCD3-specifikke polypeptider og anvendelsen deraf |
| CN100509850C (zh) * | 2003-05-31 | 2009-07-08 | 麦克罗梅特股份公司 | 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物 |
| SI1673398T1 (sl) * | 2003-10-16 | 2011-05-31 | Micromet Ag | Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| PL1976886T3 (pl) * | 2005-12-16 | 2015-06-30 | Amgen Res Munich Gmbh | Środki i metody do leczenia chorób nowotworowych |
| CA2658557C (en) * | 2006-08-14 | 2015-12-01 | Xencor, Inc. | Optimized antibodies that target cd19 |
| BRPI0921482B1 (pt) * | 2008-11-07 | 2022-09-20 | Amgen Research (Munich) Gmbh | Uso de uma construção de anticorpo de cadeia simples biespecífica cd19xcd3 no tratamento de leucemia linfoblástica aguda |
| CN104945311A (zh) * | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| NZ593593A (en) * | 2009-01-19 | 2013-11-29 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP2012528177A (ja) * | 2009-05-27 | 2012-11-12 | アボット・ラボラトリーズ | キナーゼ活性のピリミジン阻害剤 |
| KR20120085781A (ko) * | 2009-09-20 | 2012-08-01 | 아보트 러보러터리즈 | Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물 |
| ES2552655T5 (es) * | 2009-10-27 | 2021-10-27 | Amgen Res Munich Gmbh | Pauta posológica para administrar un anticuerpo biespecífico CD19xCD3 |
-
2009
- 2009-11-06 BR BRPI0921482-8A patent/BRPI0921482B1/pt active IP Right Grant
- 2009-11-06 CA CA2742249A patent/CA2742249C/en active Active
- 2009-11-06 RS RS20190593A patent/RS58827B1/sr unknown
- 2009-11-06 EP EP15185767.9A patent/EP2982696B1/en active Active
- 2009-11-06 DK DK09760483.9T patent/DK2342227T3/en active
- 2009-11-06 AU AU2009313040A patent/AU2009313040B2/en active Active
- 2009-11-06 CN CN201710366308.1A patent/CN107184977A/zh active Pending
- 2009-11-06 JP JP2011533633A patent/JP5647132B2/ja active Active
- 2009-11-06 SI SI200931306T patent/SI2342227T1/sl unknown
- 2009-11-06 HU HUE09760483A patent/HUE028175T2/en unknown
- 2009-11-06 PL PL09760483T patent/PL2342227T3/pl unknown
- 2009-11-06 LT LTEP15185767.9T patent/LT2982696T/lt unknown
- 2009-11-06 MX MX2011002927A patent/MX2011002927A/es active IP Right Grant
- 2009-11-06 WO PCT/EP2009/007970 patent/WO2010052014A1/en active Application Filing
- 2009-11-06 KR KR1020117010641A patent/KR101695327B1/ko active IP Right Grant
- 2009-11-06 RU RU2011122819/10A patent/RU2536940C2/ru active
- 2009-11-06 CN CN2009801443998A patent/CN102209728A/zh active Pending
- 2009-11-06 PT PT97604839T patent/PT2342227E/pt unknown
- 2009-11-06 ES ES15185767T patent/ES2727585T3/es active Active
- 2009-11-06 PL PL15185767T patent/PL2982696T3/pl unknown
- 2009-11-06 ES ES09760483.9T patent/ES2558434T3/es active Active
- 2009-11-06 SI SI200931967T patent/SI2982696T1/sl unknown
- 2009-11-06 EP EP09760483.9A patent/EP2342227B1/en active Active
- 2009-11-06 DK DK15185767.9T patent/DK2982696T3/da active
- 2009-11-06 RS RS20150797A patent/RS54456B1/en unknown
- 2009-11-06 US US13/127,541 patent/US20130323247A1/en not_active Abandoned
- 2009-11-06 PT PT15185767T patent/PT2982696T/pt unknown
- 2009-11-06 HU HUE15185767A patent/HUE043326T2/hu unknown
- 2009-11-06 ME MEP-2019-146A patent/ME03480B/me unknown
- 2009-11-06 NZ NZ591311A patent/NZ591311A/xx unknown
- 2009-11-06 ME MEP-2015-181A patent/ME02363B/me unknown
-
2011
- 2011-05-03 IL IL212652A patent/IL212652A/en active IP Right Grant
- 2011-05-05 ZA ZA2011/03255A patent/ZA201103255B/en unknown
- 2011-12-07 HK HK11113215.9A patent/HK1158668A1/xx unknown
-
2014
- 2014-11-06 JP JP2014226022A patent/JP5955921B2/ja active Active
-
2015
- 2015-10-06 AU AU2015238784A patent/AU2015238784A1/en not_active Abandoned
- 2015-11-03 HR HRP20151168TT patent/HRP20151168T1/hr unknown
- 2015-12-09 CY CY20151101123T patent/CY1117033T1/el unknown
- 2015-12-30 SM SM201500328T patent/SMT201500328B/it unknown
-
2016
- 2016-07-22 HK HK16108827.4A patent/HK1220705A1/zh unknown
-
2017
- 2017-08-25 AU AU2017219083A patent/AU2017219083B2/en active Active
-
2018
- 2018-11-06 AU AU2018260815A patent/AU2018260815B2/en active Active
- 2018-12-13 US US16/218,797 patent/US11597766B2/en active Active
-
2019
- 2019-05-16 HR HRP20190912TT patent/HRP20190912T1/hr unknown
- 2019-05-17 CY CY20191100527T patent/CY1122366T1/el unknown
-
2023
- 2023-02-03 US US18/164,304 patent/US20240109964A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2558434T3 (es) | Tratamiento de leucemia linfoblástica aguda | |
| ES2662929T3 (es) | Tratamiento de leucemia linfoblástica aguda pediátrica | |
| ES2930058T3 (es) | Receptores quiméricos y métodos de uso de los mismos | |
| ES2862433T3 (es) | Uso de linfocitos infiltrantes de médula ósea alogénicos tratados con ciclofosfamida postrasplante para aumentar la inmunidad antitumoral | |
| US20200155599A1 (en) | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment | |
| ES2924138T3 (es) | Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina | |
| WO2019178215A1 (en) | Methods and compositions for treating, prognosing, and diagnosing esophageal cancer | |
| US20230173095A1 (en) | Living cells engineered with polyphenol-functionalized biologically active nanocomplexes | |
| AU2021392655A1 (en) | Methods and materials for treating t cell cancers | |
| US20240207406A1 (en) | Methods and compositions comprising mhc class i peptides | |
| Ulasov et al. | The IL13α 2R paves the way for anti-glioma nanotherapy |